Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01099358 · ClinicalTrials.gov registry record · Phase 2
Study in Advanced Solid Tumors
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01099358 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants.
The verdict
NCT01099358, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary purpose of this study is to help answer the following research question(s): * To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with cisplatin \[pharmacokinetic (PK) analysis\] * To see if any drug interactions occur between cetuximab and cisplatin.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG 5 - Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01099358
The ClinicalTrials.gov registry entry for NCT01099358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01099358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01099358 about?
NCT01099358 is a clinical study titled "Study in Advanced Solid Tumors". The primary purpose of this study is to help answer the following research question(s): * To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with cisplatin \[pharmacokinetic (PK) analysis\] * To see if any drug interactions occur between cetuxima...
What is the current status of trial NCT01099358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2010-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01099358?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), 5 - Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT01099358?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.